INTERVENTIONAL VASCULAR CORPORATE PRESS RELEASES

Please find below a list of our press releases.

7 Nov 2018

BTG Sentry Bioconvertible IVC Filter 2-year Study Results Show Zero Tilt, Migration, Perforation, Fracture, or Embolization

BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of the two-year results for the SENTRY trial, at the Vascular Interventional Advances (VIVA) conference in Las Vegas. The prospective, multicenter trial of the BTG Sentry, the world’s first bioconvertible IVC filter, found that in addition to providing protection against pulmonary embolism (PE) during the transient risk period, the device also had zero instances of tilt, perforation, migration and embolization through two years of imaging-intensive follow-up.

7 Sep 2018

BTG plc acquires Novate Medical Ltd.

BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Novate Medical Ltd. (“Novate”), a medical device company focused on the prevention of pulmonary embolism (PE) in patients at high risk of venous thromboembolic events.

23 Jul 2018

OPTALYSE PE Results Published in JACC: Cardiovascular Interventions

Bothell, WA, 23 July 2018: BTG plc (LSE: BTG), the global healthcare company, highlighted the publication of OPTALYSE PE trial results in JACC: Cardiovascular Interventions. The published findings further confirm that bilateral pulmonary embolism (PE) treated in as little as 2 hours with EKOS™ Acoustic Pulse Thrombolysis™ therapy shows significant improvement in RV/LV ratio and with a very low one-year mortality rate of 2% and an equally low one-year recurrent PE rate of 2%. This is with considerably less tissue plasminogen activator (tPA) than used in previous studies1, as low as 8mg total.

21 Jun 2018

PERT Consortium and BTG Form Strategic Partnership

BTG plc (LSE: BTG), the global healthcare company, today announced at the annual PERT Consortium Meeting in Nashville, TN, a strategic partnership with the PERT Consortium to advance the science of Pulmonary Embolism (PE) treatment and promote the implementation of PERT programs across the U.S.

27 Apr 2018

OPTALYSE PE Results Presented at Society for Cardiovascular Angiography and Interventions

BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of OPTALYSE PE trial results at the Society for Cardiovascular Angiography and Interventions in San Diego, California. The findings further confirm that bilateral pulmonary embolism treated in as little as 2 hours with significantly less tissue plasminogen activator (tPA) than used in previous studies1- as low as 8mg total - show significant improvement in RV/LV ratio over both the short and long term and with a very low mortality rate of 2% and an equally low recurrent PE rate of 2%.

6 Feb 2018

OPTALYSE PE Long Term Results Reinforce Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

BTG plc (LSE: BTG), the global healthcare company, today highlighted OPTALYSE PE one year trial results, presented at the International Society on Endovascular Therapy in Florida.

13 Dec 2017

Centers Commence Enrollment in KNOCOUT PE Study to Measure the Impact of Shorter, Even Safer EKOS® Therapy Protocols for Pulmonary Embolism

BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how hospitals and patients are benefitting from a new standard of care in the treatment of Pulmonary Embolism utilizing EKOS® therapy with faster, and even safer protocols, proven effective in the OPTALYSE PE study.

5 Oct 2017

BTGplc acquires Roxwood Medical

London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.

16 Jun 2017

ACCESS PTS Study Demonstrates Efficacy of EKOS® Therapy for Post-Thrombotic Syndrome

BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th Annual Scientific Sessions in New Orleans, June 14 to 17.

22 May 2017

OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism